REG-Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
Globe Newswire•13/10/2026•02:00 ET
0
Key Highlights
- ➤Zelluna will publish Q3 2026 financial results on 5 November 2026
- ➤ZIMA-101 Phase 1 study update planned for ZI-MA4-1 therapy
- ➤Quarterly report and presentation materials due at 07:00 CET
- ➤Live results webcast scheduled for 09:00 CET on 5 November
Expert Statements
Namir Hassan, CEO of Zelluna
“For further information, please visit www.zelluna.com or contact:”
Geir Christian Melen, CFO of Zelluna
“For further information, please visit www.zelluna.com or contact:”
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.
In connection with the third quarter results, the Company will provide an update on its activities during the quarter, including progress in the ongoing Phase 1 ZIMA-101 study of ZI-MA4-1, Zelluna’s first-in-class MAGE-A4-targeting TCR-NK cell therapy for advanced solid tumours.
Get started
Create a free account to read the full story.